Short Interest Moves 13% Lower For SUPN

The most recent short interest data has been released by the NASDAQ for the 01/31/2014 settlement date, which shows a 533,963 share decrease in total short interest for Supernus Pharmaceuticals Inc ( SUPN), to 3,593,347, a decrease of 12.94% since 01/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for SUPN at the 01/31/2014 settlement increased to 725,595, as compared to 477,846 at the 01/15/2014 report. That brought "days to cover" down to 4.95, a 42.66% decrease from the 8.64 days to cover calculated at the previous short interest data release.

Top 25 S.A.F.E. Dividend Stocks »

The below chart shows the historical "days to cover" for SUPN at previous short interest release dates:

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where SUPN had been shorted as a hedge.

The chart below shows the one year performance of SUPN shares, versus its 200 day moving average. Looking at this chart, SUPN's low point in its 52 week range is $4.45 per share, with $10.20 as the 52 week high point — that compares with a last trade of $9.24.

If you liked this article you might like

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Anika Up on Strong Analyst Ratings